Tag Archive: serum-derived polyclonal treatment

May 12 2010

Approval of Therapeutic Cancer Vaccines

Last month, Dendreon was granted approval for Provenge®, the first cell based cancer vaccine for treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.  Provenge is the first cancer treatment that utilizes the strength of the patient’s own immune system to fight tumors.  This approval could mark the beginning of a …

Continue reading »